Background
Anti-nuclear antibodies (ANA) are autoantibodies against cell nucleus contents and use as biomarkers of systemic autoimmune diseases. Here, we aimed to evaluate ANA concentrations and extractable nuclear antigen antibodies (ENA) panel (U1-snRNP, snRNP/Sm, SmD1, dsDNA, SS-A/Ro 60, SS-A/Ro 52 and SS-B/La) in patients with luminal subtypes of breast cancer (BC).
Methods
Thirty-three patients were been studies for the demographical data and presence of ANA and ENA. Indirect immunofluorescence on human epithelial type 2 (HEp-2) cells kit was used for ANA assessment and AESKUBLOTS® ANA-17 comp kit was used for ENA.
Results
Fifteen (45.5%) patients were luminal A and 18 (54.5) patients were luminal B. 3 patients had ANA test positive and they were luminal A. No statistically significant association was found between ANA positivity and molecular subtype, age, body mass index, grade, tumor stage or lymph node involvement. Moreover, there were negative correlations between the U1-snRNP and dsDNA with Ki-67. Comparing with luminal A, U1-snRNP and snRNP/Sm concentrations were statistically significantly lower in luminal B tumors (p= 0.015 and 0.016 respectively). High grade tumors patients showed low concentrations of snRNP/Sm (p=0.027), but patients who had lymph node metastasis showed high concentrations of U1-snRNP (p=0.031).
Conclusion
In this study, ANA positivity was more common in patients with luminal A. U1-snRNP and snRNP/Sm concentrations were statistically significantly lower in luminal B BC. Patients with high grade tumors showed low concentrations of snRNP/Sm, but patients who had lymph node metastasis showed high concentrations of U1-snRNP. ORCID NO: 0000-0001-9333-6926
Anahtar Kelimeler: Anti-nuclear antibody (ANA), Autoantibodies, Luminal subtypes of breast cancer, Extractable Nuclear Antigen Antibodies (ENA) Panel
|
